Early administration of abciximab in patients with acute myocardial infarction improves angiographic and clinical outcome after primary angioplasty

Catheterization and Cardiovascular Interventions

Volumn 65, Issue 4, 2005, Pages 478-483

  Beeres, Saskia L M A ^a   Oemrawsingh, Pranobe V ^a   Warda, Hazem M ^a   Bechan, Ratna ^a   Atsma, Douwe E ^a   Jukema, J Wouter ^a   Van Der Wall, Ernst E ^a   Schalij, Martin J ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Acute myocardial infarction; Percutaneous coronary intervention; Platelet aggregation inhibitors

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRIC ACID DERIVATIVE; TICLOPIDINE;

ACUTE HEART INFARCTION; ADULT; AGED; ANGIOCARDIOGRAPHY; ANGIOPLASTY; ARTICLE; BLEEDING; CARDIOGENIC SHOCK; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DISEASE; DOSE TIME EFFECT RELATION; FEMALE; HEART ARREST; HEART MUSCLE REPERFUSION; HEART MUSCLE REVASCULARIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PATIENT TRANSPORT; PERCUTANEOUS CORONARY INTERVENTION; TREATMENT OUTCOME;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; CORONARY ANGIOGRAPHY; CORONARY ARTERIOSCLEROSIS; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; NETHERLANDS; PLATELET AGGREGATION INHIBITORS; POSTOPERATIVE COMPLICATIONS; PREDICTIVE VALUE OF TESTS; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 23044461259     PISSN: 15221946     EISSN: None     Source Type: Journal    
DOI: 10.1002/ccd.20432     Document Type: Article

References (22)

1. Dalby M, Bouzamondo A, Lechat P, Montalescot G. Transfer for primary angioplasty versus immediate thrombolysis in acute myocardial infarction. Circulation 2003;108:1809-1814.
2. Schömig A, Kastrati A, Dirschinger J, Mehilli J, Schricke U, Pache J, Martinoff S, Neumann FJ, Schwaiger M, for the STO-PAM1 investigators. Coronary stenting plus platelet glycoprotein IIb/IIIa blockade compared with tissue plasminogen activator in acute myocardial infarction. N Engl J Med 2000;343:385-391.
3. Tcheng JE, Kandzari DE, Grines CL, Cox DA, Effron MB, Garcia E, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Fahy M, Lansky AJ, Mehran R, Stone GW. Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the controlled abciximab and device investigation to lower late angioplasty complications. Circulation 2003;108:1316-1323.
4. EPIC investigators. Use of monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956-961.
5. Lincoff AM, Mark DB, Tcheng JE, Califf RM, Bala MV, Anderson KM, Davidson-Ray L, Knight JD, Cabot CF, Topol EJ, for the EPILOG investigators. Economic assessment of platelet glycoprotein IIb/IIIa receptor blockade with abciximab and low-dose heparin during percutaneous coronary revascularization. Circulation 2000;102:2923.
6. Topol EJ, Neumann FJ, Montalescot G. A preferred reperfusion strategy for acute myocardial infarction. J Am Coll Cardiol 2003;42:1886-1889.
7. Montalescot G, Barragan P, Wittenberg O, Ecollan P, Elhadad S, Villain P, Boulenc JM, Morice MC, Maillard L, Pansiéri M, Choussat R, Pinton P, for the ADMIRAL investigators. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001;344:1895-1903.
8. Stone GW, Grines CL, Cox DA, Garcia E, Tcheng JE, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Carroll JD, Rutherford BD, Lansky AJ, for the CADILLAC investigators. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 2002;346:957-966.
9. Chadow HL, Hauptman RE, Auker M, Rafii SE, Gunsburg MY, Giarraffa L, Strom JA. Drip and ship: a new stategy for the treatment of acute coronary syndromes. J Thromb Thrombolysis 2000;10:77-82.
10. Zorman S, Zorman D, Noc M. Effects of abciximab pretreatment in patients with acute myocardial infarction undergoing primary angioplasty. Am J Cardiol 2002;90:533-536.
11. TIMI study group. The thrombosis in myocardial infarction (TIMI) trial: phase I findings. N Engl J Med 1985;312:932-936.
12. Brener SJ, Barr LA, Burchenal JEB, Katz S, George BS, Jones AA, Cohen ED, Gainey PC, White HJ, Cheek HB, Moses JW, Moliterno DJ, Effron MB, Topol EJ, on behalf of the RAPPORT investigators. Randomized placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. Circulation 1998;98:734-741.
13. Neumann FJ, Kastrati A, Schmitt C, Blasini R, Hadamitzky M, Mehilli J, Gawaz M, Schleef M, Seyfarth M, Dirschinger J, Schömig A. Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction (ISAR-2). J Am Coll Cardiol 2000;35: 915-921.
14. Antoniucci D, Rodriguez A, Hempel A, Valenti R, Migliorini A, Vigo F, Parodi G, Fernandez-Pereira C, Moschi G, Bartorelli A, Santoro GM, Bolognese L, Colombo A. A randomized trial comparing primary infarct artery stenting with or without abciximab in acute myocardial infarction (ACE trial). J Am Coll Cardiol 2003;42:1879-1885.
15. Montalescot G, Borentain M, Payot L, Collet JP, Thomas D. Early vs late administration of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction. JAMA 2004;292:362-366.
16. Lee DP, Herity NA, Hiatt BL, Fearon WF, Rezaee M, Carter AJ, Huston M, Schreiber D, DiBattiste PM, Yeung AC. Adjunctive platelet glycoprotein Ilb/IIIa receptor inhibition with tirofiban before primary angioplasty improves angiographic outcomes: results of the Tirofiban Given in the Emergency Room before Primary Angioplasty (TIGER-PA) pilot trial. Circulation 2003;107:1497-1501.
17. van't Hof AWJ, Ernst N, de Boer MJ, de Winter R, Boersma E, Bunt T, Petronio S, Gosselink ATM, Jap W, Hollak F, Hoorntje JCA, Suryapranata H, Dambrink JHE, Zijlstra F, on behalf of the On-TIME study group. Facilitation of primary coronary angioplasty by early start of a glycoprotein 2b/3a inhibitor: results of the ongoing tirofiban in myocardial infarction evaluation (On-TIME) trial. Eur Heart J 2004;25:837-846.
18. Libby P. Coronary artery injury and the biology of atherosclerosis: inflammation, thrombosis and stabilization. Am J Cardiol 2000;86(Suppl):3J-8J.
19. Bonnefoy E, Lapostolle F, Leizorovicz A, Steg G, McFadden EP, Dubien PY, Cattan S, Boullenger E, Machecourt J, Lacroute JM, Caggagnes J, Dissait F, Touboul P, on behalf of the CAP-TIM study group. Primary angioplasty versus prehospital ribrinolysis in acute myocardial infarction: a randomised study. Lancet 2002;360:825-829.
20. Wong A, Mak KH, Chan C, Koh TH, Lau KW, Lim TT, Lim ST, Wong P, Sim LL, Lim YT, Tan HC, Lim YL. Combined fibrinolysis using reduced-dose alteplase plus abciximab with immediate rescue angioplasty versus primary angioplasty with adjunct use of abciximab for the treatment of acute myocardial infarction: Asia-Pacific Acute Myocardial Infarction Trial (APAMIT) pilot study. Catheter Cardiovasc Interv 2004;62:445-452.
21. Di Mario C, Bolognese L, Maillard L, Dudek D, Gambarati G, Manari A, Guiducci V, Patrizi G, Rusconi LC, Piovaccari G, Hibon AR, Belpomme V, Indolfi C, Olivari Z, Steffenino G, Zmudka K, Airoldi F, Panzarasa R, Flather M, Steg PG. Combined abciximab reteplase stent study in acute myocardial infarction (CARESS in AMI). Am Heart J 2004;148:378-385.
22. de Luca G, Suryapranata H, Ottenvanger JP, Antman EM. Time to delay to treatment and mortality in primary angioplasty for acute myocardial infarction. Circulation 2004;109:1223-1225.